High-affinity recombinant phage antibodies to the pan-carcinoma marker epithelial glycoprotein-2 for tumour targeting
1998

High-affinity antibodies for cancer targeting

publication Evidence: moderate

Author Information

Author(s): RC Roovers, P Henderikx, W Helfrich, E van der Linden, A Reurs, AP de Bruine, JW Arends, L de Leij, HR Hoogenboom

Primary Institution: Maastricht University

Hypothesis

The study investigates the potential of high-affinity recombinant phage antibodies targeting the EGP-2 antigen for tumor imaging and treatment.

Conclusion

The high-affinity anti-EGP-2 antibody fragments show promise for future applications in tumor targeting and immunotherapy.

Supporting Evidence

  • The MOC-31 antibody demonstrated the lowest off-rate among the tested antibodies, indicating better tumor retention.
  • High-affinity scFvs were shown to specifically bind to EGP-2-positive tissues in immunohistochemical analyses.
  • Previous studies indicated that antibodies targeting EGP-2 have been used successfully in clinical trials for cancer treatment.

Takeaway

Scientists created special antibodies that can find and stick to cancer cells, which could help doctors see and treat tumors better.

Methodology

The study involved isolating and characterizing high-affinity single-chain variable fragments (scFv) to the EGP-2 antigen, using surface plasmon resonance to determine binding kinetics.

Limitations

The study may have limitations related to the experimental conditions affecting the measured off-rates and the potential for non-binding or non-functional scFvs due to PCR errors.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication